These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11955783)

  • 1. Molecular differentiation between NS1 gene of a field strain Bluetongue virus serotype 2 (BTV-2) and NS1 gene of an attenuated BTV-2 vaccine.
    Agüero M; Arias M; Romero LJ; Zamora MJ; Sánchez-Vizcaíno JM
    Vet Microbiol; 2002 May; 86(4):337-41. PubMed ID: 11955783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of genome segments 2, 7 and 10 of bluetongue viruses serotype 2 for differentiation between field isolates and the vaccine strain.
    Bréard E; Sailleau C; Coupier H; Mure-Ravaud K; Hammoumi S; Gicquel B; Hamblin C; Dubourget P; Zientara S
    Vet Res; 2003; 34(6):777-89. PubMed ID: 14746772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serogrouping of United States and some African serotypes of bluetongue virus using RT-PCR.
    Aradaib IE; Mohamed ME; Abdalla TM; Sarr J; Abdalla MA; Yousof MA; Hassan YA; Karrar AR
    Vet Microbiol; 2005 Dec; 111(3-4):145-50. PubMed ID: 16280207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
    Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
    Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation between field and vaccine strain of bluetongue virus serotype 16.
    Monaco F; Cammà C; Serini S; Savini G
    Vet Microbiol; 2006 Aug; 116(1-3):45-52. PubMed ID: 16713688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors associated with the occurrence of undesired effects in sheep and goats after field vaccination with modified-live vaccine against bluetongue virus serotypes 2, 4 and 16.
    Savini G; Cannas A; Casaccia C; Di Gialleonardo L; Leone A; Patta C; Nicolussi P
    Vet Microbiol; 2010 Nov; 146(1-2):44-50. PubMed ID: 20537822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2
    Utrilla-Trigo S; Jiménez-Cabello L; Calvo-Pinilla E; Marín-López A; Lorenzo G; Sánchez-Cordón P; Moreno S; Benavides J; Gilbert S; Nogales A; Ortego J
    J Virol; 2022 Feb; 96(3):e0161421. PubMed ID: 34787454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
    Feenstra F; Pap JS; van Rijn PA
    Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the safety and immunogenicity of the South African bluetongue virus serotype 2 monovalent vaccine: specific detection of the vaccine strain genome by RT-PCR.
    Hammoumi S; Breard E; Sailleau C; Russo P; Grillet C; Cetre-Sossah C; Albina E; Sanchis R; Pepin M; Guibert JM; Zientara S
    J Vet Med B Infect Dis Vet Public Health; 2003 Sep; 50(7):316-21. PubMed ID: 14535928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bluetongue serotype 2 and 9 modified live vaccine viruses as causative agents of abortion in livestock: a retrospective analysis in Italy.
    Savini G; Lorusso A; Paladini C; Migliaccio P; Di Gennaro A; Di Provvido A; Scacchia M; Monaco F
    Transbound Emerg Dis; 2014 Feb; 61(1):69-74. PubMed ID: 22937914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge.
    Moreno S; Calvo-Pinilla E; Devignot S; Weber F; Ortego J; Brun A
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008942. PubMed ID: 33275608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines against bluetongue in Europe.
    Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge.
    Feenstra F; van Gennip RGP; Maris-Veldhuis M; Verheij E; van Rijn PA
    J Gen Virol; 2014 Sep; 95(Pt 9):2019-2029. PubMed ID: 24914064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High throughput detection of bluetongue virus by a new real-time fluorogenic reverse transcription-polymerase chain reaction: application on clinical samples from current Mediterranean outbreaks.
    Jiménez-Clavero MA; Agüero M; San Miguel E; Mayoral T; López MC; Ruano MJ; Romero E; Monaco F; Polci A; Savini G; Gómez-Tejedor C
    J Vet Diagn Invest; 2006 Jan; 18(1):7-17. PubMed ID: 16566253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of real-time RT-PCR as a rapid molecular approach for differentiation of field and vaccine strains of bluetongue virus serotypes 2 and 9.
    Elia G; Savini G; Decaro N; Martella V; Teodori L; Casaccia C; Di Gialleonardo L; Lorusso E; Caporale V; Buonavoglia C
    Mol Cell Probes; 2008 Feb; 22(1):38-46. PubMed ID: 17693055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
    Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Full-Genome Sequencing of Four Bluetongue Virus Serotype 11 Viruses.
    Vandenbussche F; Sailleau C; Rosseel T; Desprat A; Viarouge C; Richardson J; Eschbaumer M; Hoffmann B; De Clercq K; Bréard E; Zientara S
    Transbound Emerg Dis; 2015 Oct; 62(5):565-71. PubMed ID: 24750582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
    Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
    Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of bluetongue serotype 3 spread in Tunisia and discovery of a novel strain related to the bluetongue virus isolated from a commercial sheep pox vaccine.
    Lorusso A; Sghaier S; Di Domenico M; Barbria ME; Zaccaria G; Megdich A; Portanti O; Seliman IB; Spedicato M; Pizzurro F; Carmine I; Teodori L; Mahjoub M; Mangone I; Leone A; Hammami S; Marcacci M; Savini G
    Infect Genet Evol; 2018 Apr; 59():63-71. PubMed ID: 29386141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus.
    Jiménez-Cabello L; Utrilla-Trigo S; Calvo-Pinilla E; Lorenzo G; Illescas-Amo M; Benavides J; Moreno S; Marín-López A; Nogales A; Ortego J
    Front Immunol; 2024; 15():1440407. PubMed ID: 39072326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.